The content on this site is intended for healthcare professionals only
Dr Vincent Launay-Vacher from Pitie-Salpetriere Hospital, Paris, France talks to ecancertv at ASCO GU congress 2014 about the results of the MARS study. This study is assessing the renovascular tolerance of anti-VEGF drugs in a clinical setting.
Dr Launay-Vacher also discusses the new Cancer & the Kidney International Network C-KIN
Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC
Myeloma treatment and prognosis
The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG
Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC
![Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )](https://cdn.ecancer.org/44737-m.jpg)
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity
